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Accumulation of uremic toxins induces various uremia-related complications in patients with chronic kidney
disease, particularly those undergoing dialysis treatment. Direct interactions of uremic toxins with organ tissues are
thought to be a major pathophysiological mechanism for disease; for example, indoxyl sulfate reacts directly with
macrophages and accelerates atherosclerosis. The removal of sufficient volume of uremic toxins will prevent
uremia-related complications in dialysis patients. Hemodialysis with the use of a high-flux dialysis membrane, long
or frequent treatment, and increased blood/dialysate flow has improved removal of water-soluble small molecular
weight uremic toxins. Middle molecular weight molecules are removed more effectively with hemodialysis using a
high-flux membrane, hemodiafiltration and hemofiltration, and a direct hemoperfusion method using β2-
microglobulin adsorption column, which is useful in reducing serum β2-microglobulin levels as well as improving
dialysis-related amyloidosis-induced clinical symptoms. With improvements in dialysis therapies, removal of low and
middle molecular weight water-soluble molecules has improved; however, conventional dialysis treatment is limited
in its ability to remove protein-bound uremic toxins (PBUTs). Recent findings suggest that adsorption treatments
using oral charcoal adsorbent, mixed matrix membrane hollow fiber, and additive charcoal in the dialysate, in
addition to conventional dialysis treatment, may effectively remove a substantial amount of PBUTs. Further
improvement of renal replacement therapy, including dialysis and additional therapeutic strategies, is needed for
better clearance of small and middle molecular weight molecules and PBUTs, which will lead to improved survival
and quality of life for dialysis-dependent chronic kidney disease patients.
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Patients with chronic kidney disease (CKD), particularly
those undergoing dialysis treatment, develop various sys-
temic complications, such as cardiovascular disease,
mineral and bone disorders, and infectious disease. One
of the reasons underlying the development of these
complications is direct or indirect interactions between
various uremic toxins and organ tissues [1–3]. Thus,
renal replacement therapies must effectively remove a* Correspondence: yamamots@med.niigata-u.ac.jp
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survival and prevent CKD-related complications. With
progress in dialysis therapies, removal of low and middle
molecular weight water-soluble molecules has improved;
however, conventional dialysis treatment is limited in its
ability to remove protein-bound uremic toxins (PBUTs)
owing to their binding to large molecular proteins [4]. In
this article, we review characteristics of uremic toxins,
particularly PBUTs, as well as recent progress and future
perspective on therapeutic strategies for removal of
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Progressive kidney disease induces uremic syndrome,
with the retention of various solutes that are normally
excreted by the kidney. Solutes with biological toxicity,
direct or indirect, are called “uremic toxins” (Table 1)
[5]. A literature search identified 88 uremic toxins from
621 articles, and these were classified into three groups
according to molecular weight and binding properties,
such as water-soluble low molecular weight, middle mo-
lecular weight, and protein-bound solutes [6].
There are 40 kinds of free water-soluble low molecular
weight molecules (<0.5 kDa) that are considered uremic
toxins. For example, recent findings showed that serum
level of trimethylamine-N-oxide (TMAO), molecular
weight 75, is increased in hemodialysis patients [7], and
clinical research demonstrated an association between
serum level of TMAO and cardiovascular disease [8].
Dietary intake of phosphatidylcholine serves as fuel for
intestinal microbiota, resulting in the production of tri-
methylamine, which is oxidized to TMAO in the liver.
TMAO accelerates atherosclerosis; a direct reaction with
macrophages was demonstrated in a mouse model [9].
Thus, elevated TMAO level in dialysis patients acceler-
ates atherosclerosis by inducing functional abnormalities
of macrophages. Uremic toxins with a small molecular
weight are easily removed with conventional dialysis
treatment. Kt/V urea is widely used to assess the effi-
ciency of small uremic toxin removal in dialysis patients.
Previous clinical studies showed that single-pool Kt/V
urea up to 1.8 correlated with improved survival in
Japanese hemodialysis patients [10] while high dose
hemodialysis with Kt/V urea 1.71 did not show signifi-
cant benefit for mortality as compared to standard dose
of dialysis with Kt/V urea 1.32 [11]. According to those
clinical studies, Japanese Society of Dialysis Therapy
(JSDT) recommends to keep Kt/V urea more than 1.2
for hemodialysis patients for the better survival [12].
However, evaluation of Kt/V urea alone is not adequate
to determine dialysis adequacy, because (1) there are
limited reports concerning toxicity of urea, (2) distribu-
tion volume of urea is different from that of other water-
soluble small molecules, and (3) Kt/V urea dose did not
evaluate the adequacy of removal of middle molecularTable 1 Requirements for a uremic toxin
1. The toxin is a unique chemical entity.
2. Quantitative analysis of the toxin in biological fluids is possible
3. The levels of the toxin in biological fluids increase with deterioration
of kidney function.
4. A positive relationship between toxin level in biological fluids and
manifestations of uremic syndrome is present.
5. Administration of the toxin at concentration seen in patients with
kidney disease shows toxic effects related to uremic syndrome both
in vivo and in vitro.weight and protein-bound molecules [13]. Thus, clini-
cians should consider Kt/V as a minimum requirement
parameter, and consider total dialysis adequacy to in-
clude not only Kt/V but also other middle molecular
weight- and PBUT-related markers.
There are 25 types of middle molecular weight mole-
cules, those molecular weight from 0.5 to 60 kDa, such
as β2-microglobulin (β2-m) and α1-macroglobulin.
Clearance of middle molecular weight molecules by a
hemodialyzer is not as great as that of small molecules
owing to their larger molecular weight; however, the use
of high-flux dialyzer or hemodiafiltration results in bet-
ter clearance of middle molecular weight molecules than
hemodialysis with low-flux dialyzer. β2-m, a representa-
tive middle molecular weight molecule (11.8 kDa),
correlates with survival in dialysis patients. In the ran-
domized hemodialysis (HEMO) study, the relationship
between serum β2-m levels or dialyzer β2-m clearance
and mortality over a period of 2.84 years was analyzed
[14]. In time-dependent Cox regression models, pre-
dialysis serum β2-m levels were associated with all-cause
mortality in maintenance hemodialysis patients [14]. In
Japan, Okuno et al. reported that all-cause and non-
cardiovascular mortality in hemodialysis patients with a
serum β2-m level greater than 32.2 mg/L were higher
than that in those with a level lower than 32.2 mg/L
[15]. Although HEMO study did not demonstrate an as-
sociation between serum β2-m level and cardiovascular
mortality [14], several studies reported the possibilities
of a relationship between β2-m and cardiovascular dis-
ease. A report showed that serum level of β2-m in CKD
patients, including those undergoing chronic dialysis,
was associated with vascular calcification as well as car-
diovascular events/mortality during a mean follow-up of
969 days [16]. A cross-sectional study revealed that
serum β2-m level correlated with heart valve calcifica-
tion, which is associated with carotid intima media
thickness in dialysis patients [17]. Another clinical study
showed that serum β2-m levels positively correlated with
several cardiovascular risk factors, such as highly sensi-
tive C-reactive protein, troponin-T, myeloperoxidase,
and N-terminal pro-B-type natriuretic peptide, and in-
versely correlated with prealbumin and ankle-brachial
index [18]. In addition to all-cause and cardiovascular
mortality, mortality due to infections was also increased
in dialysis patients with high serum β2-m levels [19].
These reports indicate that a high serum level of β2-m is
associated with mortality, partially due to cardiovascular
disease and infection in patients undergoing mainten-
ance hemodialysis treatment. There is no data to show
that increase of β2-m removal by renal replacement ther-
apy induces better survival in dialysis patients, and fur-
ther studies are needed to understand it. With present
evidences, JSDT recommends the maintenance of serum
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peritoneal dialysis patients, serum β2-m level is con-
versely related with residual kidney function [20], and
patients should switch their renal replacement therapy
from peritoneal dialysis to hemodialysis when the serum
level of β2-m increases above 30 mg/L [21]. From an-
other point of view, β2-m is a precursor protein for
dialysis-related amyloidosis (DRA). β2-m-related amyloid
fibrils are formed and deposited primarily in osteoarticu-
lar joint tissues, resulting in various osteoarticular di-
sorders, such as carpal tunnel syndrome, destructive
spondyloarthropathy, and bone cysts in dialysis patients
[22]. Duration of dialysis treatment is one of the risk fac-
tors for osteoarticular disorders, and the accumulation
of β2-m during long-term dialysis treatment may be re-
lated to this development [23]. Conformational change
of the β2-m molecule is needed for amyloid fibril forma-
tion in the in vitro setting [24], and intermediate states
of β2-m molecules are found in hemodialysis patients
[25]. Thus, the accumulation and conformational change
of β2-m molecules are required for the development of
DRA during prolonged dialysis treatment.
PBUTs are strongly protein-bound and are difficult to
remove with conventional hemodialysis treatment. For
example, indoxyl sulfate (IS) and p-cresyl sulfate (PCS)
are 97.7 and 95.1 % protein-bound, respectively, and re-
duction rates of IS and PCS by standard hemodialysis
are only 31.8 and 29.1 %, respectively [26] (Table 2).
Recently, the relationships between several PBUTs and
mortality in CKD patients were reported. Serum level of
IS increased with the progression of CKD, particularly in
patients undergoing dialysis treatment. IS was associated
with increased cardiovascular mortality in CKD patients
as well as aortic calcification and pulse wave velocity [2].
Indoleacetic acid (IAA) showed trends similar to IS, andTable 2 Characteristics of protein-bound uremic toxins
Uremic toxins Pre-dialysis concentratio
Indoxyl sulfate 2.99 ± 0.18
Indoxyl glucuronide 0.25 ± 0.03
Indoleacetic acid 0.12 ± 0.01
P-Cresyl sulfate 3.71 ± 0.28
P-Cresyl glucuronide 0.58 ± 0.09
Phenyl sulfate 1.35 ± 0.15
Phenyl glucuronide 0.06 ± 0.01
Phenylacetic acid 0.05 ± 0.01
Phenylacethyl glutamine 4.15 ± 0.37
Hippuric acid 4.43 ± 0.53
4-Ethylphenyl sulfate 0.0242 ± 0.004
3-Carboxy-4-methyl-5-propyl-2-furanpropionic acid 2.11 ± 0.13
Serum samples were obtained from patients undergoing maintenance hemodialysi
0.97 ± 0.02 g/kg/day, respectivelymultivariate analysis showed that IAA, but not IS and
PCS, remained a significant predictor of mortality and
cardiovascular events [27]. Direct interactions of uremic
toxins with blood vessel cells are thought to be a major
pathophysiological mechanism for the development of
cardiovascular disease in CKD patients [1]. When vari-
ous types of PBUTs at the concentration found in dialy-
sis patients, with or without albumin, were exposed to
human umbilical vein endothelial cells (HUVEC), pro-
duction of reactive oxygen species (ROS) from cells in-
creased most intensely with IS, followed by indole
glucuronide, hippuric acid, and PCS, in the absence of
albumin. Even in the presence of albumin, IS and 3-
carboxy-4-methyl-5-propyl-2-furanpropionic increased
ROS production form HUVEC in vitro [26]. When mac-
rophages differentiated from THP-1 cells were exposed
to IS in vitro, IS decreased cell viability but promoted
macrophage inflammatory cytokine production as well
as ROS production. IS also reduced macrophage choles-
terol efflux and decreased ATP-binding cassette trans-
porters G1 expression [28]. These results indicate that
direct interactions of IS with macrophages may be a
major cause of atherosclerosis acceleration in patients
with CKD (Fig. 1). In an animal study, atherosclerotic le-
sions in apolipoprotein E deficient mice were signifi-
cantly accelerated by uninephrectomy or subtotal
nephrectomy as compared to those with normal kidney
function [29–31]. When the mice were treated with an
oral charcoal adsorbent AST-120 after renal ablation,
AST-120 treatment dramatically ameliorated the kidney
damage-induced atherosclerosis [29]. These mice had less
aortic deposition of IS, as well as reduced aortic expression
of inflammatory cytokines. These results suggest that
PBUTs, particularly IS, accelerate atherosclerosis as a result
of direct interaction with macrophages and endothelial cellsns (mg/dL) Protein binding (%) Reduction rate with hemodialysis (%)
97.7 ± 0.2 31.8 ± 1.4
59.6 ± 1.5 79.6 ± 0.9
94.1 ± 0.6 44.3 ± 1.5
95.1 ± 0.6 29.1 ± 1.7
32.3 ± 2.6 80.7 ± 1.1
90.7 ± 0.9 65.2 ± 1.4
76.1 ± 1.3 69.2 ± 8.6
60.5 ± 2.4 35.0 ± 7.0
44.9 ± 2.1 75.7 ± 1.0
48.3 ± 2.5 68.9 ± 1.6
4 99.3 ± 0.1 5.5 ± 2.5
99.7 ± 0.1 −30.5 ± 3.1
s whose Kt/V and protein-catabolic rate were 1.40 ± 0.03 and
Fig. 1 Indoxyl sulfate (IS) induces macrophage foam cell formation in an atherosclerotic lesion. IS, a protein-bound uremic toxin, reacts directly
with macrophages and induces production of inflammatory cytokines as well as impairment of cholesterol efflux to high-density lipoprotein,
leading to macrophage foam cell formation
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damage, with decreased serum/urine levels of IS and oxida-
tive stress markers, such as 8-hydroxy-2’-deoxyguanosine
and aclorein, in a rat model [32]. Concerning bone dis-
ease, thyroparathyroidectomy and progressive partial
nephrectomy in rats induced an increase of the min-
eral/matrix ratio and carbonate substitution as well
as decreased storage modulus and crystallinity as
compared to thyroparathyroidectomy alone. AST-120
abolished kidney damage-induced bone abnormalities
and decreased serum IS concentration [33]. These
findings suggest that uremic toxins react with vari-
ous organs, directly or indirectly, and removal of
these toxins with AST-120 will result in improved
organ function. Clinical studies have not shown
clearly that AST-120 had beneficial effect on CKD-
related complications as compared to rodent studies,
probably owing to the dose of AST-120. Many basic
and clinical research studies suggest the importance
of PBUTs in various CKD-related complications;
however, there is still no recommendation concern-
ing adequate concentration or removal of PBUTs for
improved survival, and commercial measurements of
these toxins are not clinically available.Removal of uremic toxins by renal replacement therapies
Current progress in renal replacement therapies has im-
proved the removal of various uremic toxins in dialysis
patients, but current methods are insufficient to prevent
CKD-related systemic complications.1) Hemodialysis
Removal of uremic toxins, particularly middle
molecular weight molecules, has been improved
with hemodialysis using the high-flux dialyzer
membrane [34]. A large randomized, controlled trial
showed that high dose hemodialysis increased Kt/V
urea, but not clearance of β2-m, and use of a high-
flux dialyzer increased clearance of β2-m, but not
Kt/V urea [11]. The removal of small and middle
molecular weight molecules by hemodialysis is
dependent on treatment time, even with slow flow
of both blood and dialysate [35]. Compared with
hemodialysis for 4 h with 350 ml/min blood and
dialysate flow rate, 8-h dialysis sessions with 190 ml/
min blood and dialysate flow rate increased the re-
moval of urea and β2-m by 22.6 and 39.2 %, respect-
ively. Reduction rate of IS and PCS are 31.8 and
29.1 %, respectively, with regular hemodialysis treat-
ment [26], and there was a trend towards the in-
creased removal of these molecules with 8-h
hemodialysis as compared to routine 4-h treatment
[35]. Another clinical study showed that daily
hemodialysis maintained lower serum levels of IS and
IAA as well as lower levels of non-protein-bound sol-
utes [36]. Recent finding showed that the time exten-
sion for hemodialysis resulted in improved removal of
not only small and middle molecular weight mole-
cules but also some PBUTs as to standard
hemodialysis when patients used the same high-flux
dialyzer, dialysis flow, and blood flow [37]. Dialyzers
also affect the efficiency of PBUT extraction. Large
Fig. 2 Schematic representation of blood flow through the dialyzer
and β2-microglobulin (β2-m) adsorption column. The column system
is designed for direct hemoperfusion and is used in combination
with a hemodialyzer downstream of the β2-m adsorption column
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showed much removal of IS, IAA, and hippuric acid
than low-flux cellulose triacetate membranes (LF)
(removal rate of IS; SF 32.5 ± 8.5 % vs LF 24.8 ± 6.5 %)
[38]. These studies suggest that prescriptions for
hemodialysis, such as the type of dialysis membrane,
treatment time, and blood/dialysate flow rates, affect
the clearance of not only small and middle molecular
weight molecules but also some PBUTs; however,
these changes remain insufficient to prevent CKD-
related complications.
2) Hemodiafiltration and hemofiltration
Hemodiafiltration (HDF) and hemofiltration (HF)
are more effective to remove water-soluble middle
molecules than hemodialysis due to the increase of
convection, but the effect is small for PBUTs. A
crossover trial clinical to examine the removal of
uremic toxins by hemodialysis or post-dilution HDF
was conducted [39]. Post-dilution HDF increased
the instantaneous plasma clearance of urea and β2-
m as compared to hemodialysis; however, clearance
of both total and free IS and PCS did not increase
with the change from hemodialysis to HDF [39]. In
the comparison of different convective strategies, re-
moval of small molecules, such as urea and creatin-
ine, was more effective with post-dilution HDF than
pre-dilution HDF and HF [40]. In the case of middle
molecular weight molecules, post-dilution HDF is
superior to pre-dilution HDF for the removal of β2-
m. For some PBUTs, including hippuric acid, IS, and
PCS, both pre- and post-dilution HDF are superior
to post-dilution HF [40]. It is difficult to compare
the properties to remove uremic toxins between
HDF and HD using SF; however, these findings
suggest that physicians should choose the types of
convection based upon the type of uremic toxins to
be removed most efficaciously for each dialysis
patient.
3) β2-microglobulin adsorption column
The Lixelle® column was developed for direct β2-m
adsorption from circulating blood and is used
primarily for hemodialysis patients with progressive
DRA. Lixelle contains a porous cellulose bead filling
with a sodium citrate buffer. The porous cellulose
beads were designed to selectively adsorb β2-m,
having the appropriate pore size and hydrophobic
interaction. This adsorption column system is
designed for direct hemoperfusion and is used in
combination with a dialyzer that is the downstream
of the Lixelle column (Fig. 2). There are several
clinical trials demonstrating the effect of Lixelle on
the reduction of β2-m in patients undergoing
hemodialysis [41–46]. The Lixelle column induces a
60.0–78.9 % reduction in serum β2-m with 157–300 mg removal; the serum level of β2-m decreased
from 27.1–29.0 to 6.8–13.5 mg/L [41, 42, 46].
According to a prospective multicenter study, a
Lixelle column (S-35) placed in series with a
polysulfone dialyzer increased serum β2-m reduction
in patients undergoing hemodialysis as compared to
hemodialysis treatment without Lixelle (reduction
rate: 74.1 ± 6.1 vs 60.1 ± 6.3 %) [46]. These clinical
studies also showed improvements in DRA-related
symptoms, such as joint pain and activities of daily
living [41, 43–48]. Gejyo et al. surveyed the clinical
effect of Lixelle in hemodialysis patients with DRA.
Of 345 patients with DRA, 56.2 % patients treated
with Lixelle for 3.5 ± 2.7 years reported improve-
ment in their DRA-related symptoms [47]. Some
clinical study showed shrinkage in the size of bone
cysts owing to amyloidosis when evaluated by X-ray
[41, 49]; thus, this direct hemoperfusion treatment
may decrease the deposition of β2-m-related amyl-
oid. In addition, the Lixelle column adsorbs not only
β2-m but also other molecules, including inflamma-
tory cytokines, with molecular sizes ranging from
4000 to 20,000 Da [50]. This may be another explan-
ation for the improvement in DRA-related clinical
symptoms.
4) Other treatments
The removal of water-soluble small and middle mo-
lecular weight uremic toxins has been improved with
hemodialysis, HDF/HF, or direct hemoperfusion;
however, the efficacy of these dialysis treatments in
the removal of PBUTs is small. Even in the case of
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kidney function is more important to decrease
PBUTs than peritoneal clearance [51, 52]. Thus,
alternative or additional therapeutic strategies will be
needed for future blood purification therapies to
prevent PBUT-induced dialysis-related complications,
including cardiovascular disease.The oral charcoal adsorbent AST-120 is known to re-
duce serum levels of IS through the adsorption of indole,
which is converted from dietary tryptophan in the
gastrointestinal tract in non-dialysis CKD patients [53].
Although randomized, controlled trials did not clearly
demonstrate inhibited progression of renal disease in non-
dialysis CKD patients with the use of AST-120 [54, 55], a
clinical study showed that the treatment in pre-dialysis
may affect the prognosis after initiation of dialysis treat-
ment [56]. Thus, AST-120, the adsorption treatment, may
show more benefit for prognosis in dialysis patients be-
cause this population has much higher levels of circulating
PBUTs [2, 26]. When anuric patients undergoing mainten-
ance hemodialysis treatment used AST-120 6 g/day for
2 weeks, total and free IS levels in the predialysis session
decreased significantly with AST-120 treatment from 3.06
to 1.63 mg/dL and from 0.098 to 0.023 mg/dL, respect-
ively [57]. The use of AST-120 also reduced the PCS (total
and free) and phenyl sulfate (free). We also evaluated
changes in the oxidative stress markers with AST-120
treatment in dialysis patients and found that the use of
AST-120 induced significant reduction in oxidized albu-
min content as well as 8-isoprostane [57]. Another study
investigated the effect of a mixed matrix membrane
(MMM) for the removal of protein-bound uremic toxins
[58]. The MMM hollow fiber consists of a porous macro-
void free polymeric inner membrane layer strongly at-
tached to the activated carbon-containing outer MMM
layer; it absorbed 2.27 mg PCS/g membrane and 3.58 mg
PCS/g membrane in diffusion as well as convection for
4 h from human plasma [58]. The addition of charcoal to
the dialysate increased the clearance of indican (12 vs
5 ml/min without sorbent), PCS (9 vs 4 ml/min without
sorbent), and p-cresol (35 vs 14 ml/min without sorbent)
in artificial plasma [59]. Taken together, these adsorption
treatments have the potential to remove significantly more
PBUTs when added to conventional dialysis treatment,
and removal with adsorption may be a key strategy in next
generation renal replacement therapy.
Conclusions
Recent progress in dialysis treatment has increased the re-
moval of uremic toxins, but these improvements are insuf-
ficient to prevent CKD-related complications and improve
mortality, particularly concerning levels of PBUTs. Further
improvements in renal replacement therapy includinghemodialysis or additional therapeutic strategies will be
needed for better clearance of small and middle molecular
weight molecules as well as PBUTs.
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